# US 2018/0022719 A1 · Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022719 A1
- Document ID: US20180022719A1
- Status: Published application
- Kind: A1
- Application number: 15/593,538
- Filed: 2017-05-12
- Published: 2018-01-25
- Earliest claimed: 2007-10-26
- Assignees: Piramal Imaging SA
- Applicants: Piramal Imaging SA
- Inventors: Lutz LEHMANN; Andrea THIELE; Tobias HEINRICH; Thomas BRUMBY; Christer HALLDIN; Balazs GULYAS; Sangram NAG
- Web page: https://patentgrep.com/patent/US20180022719A1

## CPC

- C07D 291/08: condensed with carbocyclic rings or ring systems
- A61K 51/04: Organic compounds
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/00: Introduction of isotopes of elements into organic compounds {; Labelled organic compounds per se}
- C07C 211/42: with six-membered aromatic rings being part of the condensed ring systems
- C07C 309/66: Methanesulfonates
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A61K 49/0433: {containing an organic halogenated X-ray contrast-enhancing agent}
- A61K 51/00: Preparations containing radioactive substances for use in therapy or testing in vivo
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

## Claims

### Claim 1

A compound of formula Ia
wherein
W is —C(U1)(U2)—C≡CH,
U1 and U2 are each independently hydrogen or deuterium, wherein at least one of U1 and U2 is deuterium,
A is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (C1-C10)alkyl, G4-(C2-C4)alkynyl, G4-(C1-C4)alkoxy, (G4-(C1-C4)alkyl)aryl, (G4-(C1-C4)alkoxy)aryl, (G4-(C1-C4)alkyl)aryl, or (G4-(C1-C4)alkoxy)aryl,
G1, G2, G3 and G4 are independently and individually, at each occurrence, selected hydrogen, (C1-C4)alkyl, L, and —(C1-C6)alkyl-L,
with the proviso that exactly one of G1-G4 is L or —(C1-C6)alkyl-L,
L is a leaving group, or L is F,
n is an integer from 0 to 6,
m is an integer from 0 to 4,
including all isomeric forms of said compound, including but not limited to enantiomers and diastereoisomers as well as racemic mixtures,
and any pharmaceutically acceptable salt, ester, amide, complex or prodrug thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound according to claim 1, wherein A is substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, (C1-C4)alkyl, G4-(C3-C4), alkynyl, G4-(C1-C3)alkoxy, (G4-(C1-C3)alkyl)phenyl, or (G4-(C1-C3)alkoxy)phenyl.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein A substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, (G4-(C1-C3)alkyl)phenyl, (G4-(C1-C3)alkoxy)phenyl, hydroxy-phenyl, halo-phenyl, methoxy-phenyl, dimethoxy-phenyl, trifluormethyl-phenyl, or ((C1-C4)alkyl)-phenyl.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein A is substituted or unsubstituted phenyl, (G4-(C1-C3)alkoxy)phenyl, hydroxyl-phenyl, fluorophenyl, methoxyphenyl, or methylphenyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein G1, G2, G3 and G4 are independently and individually, at each occurrence, hydrogen, (C1-C4)alkyl, L, or —(C1-C4)alkyl-L,
with the proviso that exactly one of G1-G4 is L or —(C1-C4)alkyl-L.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein G1, G2, G3 and G4 are independently and individually, at each occurrence, hydrogen, methyl, L, or —(C1-C2)alkyl-L, with the proviso that exactly one of G1-G4 is L or —(C1-C2)alkyl-L.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein G1, G2, G3 and G4 are independently and individually, at each occurrence, hydrogen, methyl, L, or -methyl-L, with the proviso that exactly one of G1-G4 is L or -methyl-L.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein L is halo, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, nona-fluorobutylsulfonyloxy, (4-bromo-phenyl)sulfonyloxy, (4-nitro-phenyl)sulfonyloxy, (2-nitro-phenyl)sulfonyloxy, (4-isopropyl-phenyl)sulfonyloxy, (2,4,6-tri-isopropyl-phenyl)sulfonyloxy, (2,4,6-trimethyl-phenyl)sulfonyloxy, (4-tertbutyl-phenyl)sulfonyloxy, or (4-methoxy-phenyl)sulfonyloxy.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein L is chloro, bromo, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, (4-bromo-phenyl)sulfonyloxy, (4-nitro-phenyl)sulfonyloxy, (4-isopropyl-phenyl)sulfonyloxy, or (2,4,6-tri-isopropyl-phenyl)sulfonyloxy.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The compound according to claim 1, wherein L is not F.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein L is 18F.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein L is 19F.

### Claim 15 (depends on 1)

A method of synthesis of a compound according to claim 1, said method comprising reacting a compound according to formula Ia in which L is a leaving group with an F-fluorinating agent in which F is 18F or 19F.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said F-fluorinating agent is 4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane K F, KF, HF, KH F2, CsF, NaF, or a tetraalkyl ammonium salt of F, wherein F=18F or 19F.

### Claim 17 (depends on 13)

A method of synthesis of a compound as defined in claim 13, comprising:
F-fluorinating a compound of formula V
with an F-fluorinating agent to yield a compound of formula IV,
substituting said compound of formula IV with a compound of formula VI
wherein F is 18F or 19F,
a is an integer from 0 to 4,
B is a leaving group,
W2 is W,
A2 is R12—O-aryl, R12—O-heteroaryl, aryl, heteroaryl, such as furanyl, (C1-C10)alkyl, (C2-C4)alkynyl, (C1-C4)alkoxy, ((C1-C4)alkoxy)aryl, or ((C1-C4)alkyl)aryl,
R9 and R10 are independently and individually, at each occurrence, (C1-C6)alkyl or hydrogen,
R11 is (C1-C6) alkyl or R12,
R12 is hydrogen,
d is an integer from 0 to 4, and
wherein said F-fluorinating agent is 4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane K F, KF, HF, KH F2, CsF, NaF, or a tetraalkyl ammonium salt of F wherein F=18F or 19F,
with the proviso that the compound of formula VI contains exactly one R12.

### Claim 18 (depends on 17)

The method according to claim 17, wherein B is iodo, bromo, chloro, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, or nona-fluorobutylsulfonyloxy.

### Claim 19 (depends on 17)

The method according to claim 17, wherein A2 is R12—O-phenyl, phenyl, furanyl, (C1-C4)alkyl, (C3-C4)alkynyl, (C1-C3) alkoxy and substituted phenyl.

### Claim 20 (depends on 17)

The method according to claim 17, wherein R9 and R10 are independently and individually, at each occurrence, (C1-C4)alkyl or hydrogen.

### Claim 21 (depends on 17)

The method according to claim 17, wherein R11 is (C1-C4)alkyl or R12.

### Claim 22 (depends on 1)

A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 23 (depends on 13)

A composition comprising a compound according to claim 13 and a pharmaceutically acceptable carrier or diluent.

### Claim 24 (depends on 14)

A composition comprising a compound according to claim 14 and a pharmaceutically acceptable carrier or diluent.

### Claim 25 (depends on 12)

A composition comprising a compound according to claim 12 and a pharmaceutically acceptable carrier or diluent.

### Claim 26 (depends on 1)

A compound according to claim 1 for use as a pharmaceutical or diagnostic agent or imaging agent.

### Claim 27 (depends on 1)

Use of a compound according to claim 1 for the manufacture of a medicament for the treatment and/or diagnosis and/or imaging of diseases of the central nervous system (CNS).

### Claim 28 (depends on 13)

A compound according to claim 13 for use as a diagnostic agent or imaging agent.

### Claim 29 (depends on 12)

A kit comprising a sealed vial containing a predetermined quantity of a compound according to claim 12.

### Claim 30 (depends on 13)

A method for detecting the presence of monoamine oxidase in a patient's body, said method comprising:
introducing into a patient's body a detectable amount of a compound according to claim 13, and
detecting said compound or said composition by positron emission tomography (PET).

### Claim 31 (depends on 1)

A method of treatment of a disease of the central nervous system comprising administering to a patient a suitable quantity of a compound according to claim 1.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The compound according to claim 1, wherein both U1 and U2 are deuterium.

### Claim 35 (depends on 1)

A compound according to claim 1, wherein L is 18F or 19F.

### Claim 36 (depends on 1)

A compound according to claim 1, wherein n is an integer from 0 to 3.

### Claim 37 (depends on 1)

A compound according to claim 1, wherein n is an integer from 0 to 2.

### Claim 38 (depends on 1)

The compound according to claim 1, wherein L is a leaving group selected from chloro, bromo, iodo, mesyloxy, tosyloxy, trifluormethylsulfonyloxy, nona-fluorobutylsulfonyloxy, (4-bromo-phenyl)sulfonyloxy, (4-nitro-phenyl)sulfonyloxy, (2-nitro-phenyl)sulfonyloxy, (4-isopropyl-phenyl)sulfonyloxy, (2,4,6-tri-isopropyl-phenyl)sulfonyloxy, (2,4,6-trimethyl-phenyl)sulfonyloxy, (4-tertbutyl-phenyl)sulfonyloxy, and (4-methoxy-phenyl) sulfonyloxy.

### Claim 39 (depends on 30)

The method according to claim 30, wherein said method is for imaging a disease of the central nervous system in said patient.

### Claim 40 (depends on 13, 31)

The method according to claim 31, wherein said compound is a compound according to claim 13.

### Claim 41 (depends on 14, 31)

The method according to claim 31, wherein said compound is a compound according to claim 14.
